欧盟委员会(EC)批准了艾力雅 8mg(阿柏西普8mg114.3mg/ml注射液)在欧盟的标签扩展延长治疗间隔长达6个月

智通财经
01 Jul
欧盟委员会(EC)批准了艾力雅 8mg(阿柏西普8mg114.3mg/ml注射液)在欧盟的标签扩展延长治疗间隔长达6个月用于治疗两种主要视网膜疾病即新生血管(湿性)年龄相关性黄斑变性(nAMD)和由糖尿病黄斑水肿(DME)引起的视力损害。艾力雅 8mg是欧盟首个也是唯一一个治疗nAMD和DME患者的治疗间隔长达6个月的抗血管内皮生长因子(VEGF)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10